# A Clinical Study Evaluating the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD Patients

> **NCT07331402** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- COPD Patients

## Interventions

- **DRUG:** HSK39004 inhalation suspension

## Key facts

- **NCT ID:** NCT07331402
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-28
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-08-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07331402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07331402, "A Clinical Study Evaluating the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07331402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*